The anti-cancer agents of ErbB inhibitors namely, ZD1839, PD153035 and OSI-774, all ameliorate the deficits of acoustic prepulse inhibition in the animal models established by neonatal EGF injection and hippocampal lesion without apparent adverse influence32,33. Here, EGFR is linked to cancer.